Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01939184 · ClinicalTrials.gov registry record · Phase 2
Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
A Phase 2 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 2
- Development phase
- 796
- Enrollment target
NCT01939184: Completed Phase 2 study, sponsored by Warner Chilcott.
NCT01939184 is a Phase 2 study that has completed, run by Warner Chilcott. The registered enrollment target is 796 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (498% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01939184, a Phase 2 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 796 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
Primary Outcome
Sum of Questions 1-7.
Interventions
- OTHER Placebo
- DRUG WC3055
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 796 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
What the finished NCT01939184 record still lists
NCT01939184 is an interventional study that assigns participants to a tested intervention. The registered 796 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (498% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01939184 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01939184 about?
NCT01939184 is a clinical study titled "Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia". The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.
What is the current status of trial NCT01939184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 796 participants. The study started on 2013-08. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01939184?
The interventions under investigation include: Placebo (OTHER), WC3055 (DRUG).
Who is sponsoring clinical trial NCT01939184?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01939184's enrollment target sits among peer trials
796 40th of 2000 higher than 1,961 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05150691 · 796 participants · Phase 1
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- NCT06208150 · 795 participants · Phase 3
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- NCT06724172 · 795 participants · NA
CHIME: Comparing Health Interventions for Maternal Equity
- NCT06051058 · 798 participants · NA
Care Transitions App for Patients With Multiple Chronic Conditions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia